AiCure is an AI and advanced data analytics company targeting the healthcare industry. Our proprietary intelligent software captures and understands video, audio, and behavioral data to establish the link between patients, disease and treatment.

Validated to be accurate and to modify behavior

Applications in drug development and population health

A patented artificial intelligence foundation

Developing new paradigms to understand treatment response.

Built on a foundation of longitudinal patient data

Accurate confirmation of medication ingestion

Validated against plasma blood levels

Behavior modification

20% - 60% improvements according to blood levels

Rich data fuels predictive insights

Over 1 Million behavioral interactions with IMA

Reduces medical costs for payors
Reduces trial failure for pharma companies
See our peer-reviewed publications

In drug development, we are defining new methodologies and enrichment strategies

Clear value is essential in understanding the application of new technology. AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials. AiCure is also demonstrating significant results by introducing new trial methodologies such as placebo lead-in periods, micro-reimbursements, and other approaches directly correlated with patient engagement and clinical endpoints.

Test tube

For payors, we are reducing medical costs and waste

Medication adherence is one of the few parameters in healthcare that is directly linked to medical costs. AiCure has demonstrated significant savings for some of the largest payors and states by ensuring high-risk patient populations stay on therapy.

Fingerprint reader

For science and the healthcare industry, we are developing novel clinical endpoints through computational diagnostics

AiCure is pioneering a new set of tools to help researchers and clinicians understand and predict how patients respond to treatment. Advances in artificial intelligence allow computers to capture physiological datapoints that characterize expressivity, psychomotor function, and cognition. Whether a patient has schizophrenia or congestive heart failure, the degree to which they are able to adhere and respond to treatment depends in great part on their mood, their ability to move and to concentrate. AiCure is leading a multi-stakeholder R&D effort with industry and academia to develop these transdiagnostic domains and novel sensitive endpoints.

Computational diagnosis

AiCure News

December 13, 2019

PM360 ANNOUNCES THE SELECTIONS FOR ITS 8th ANNUAL INNOVATIONS ISSUE

The healthcare industry’s most innovative companies, startups, divisions, products, services, and strategies of 2019. NEW YORK, NY, December, 13 2019:…

December 3, 2019

The Uptick in AI Use Will Bring Pharma Into the Future Faster

The Uptick in AI Use Will Bring Pharma Into the Future Faster By Robin Robinson Nov/Dec 2019 The top…

December 3, 2019

Technology Plus Science: New Company Model?

Technology Plus Science: New Company Model? By Robin Robinson Nov/Dec 2019 We asked a variety of experts what would…

November 28, 2019

What if…

We provided our community of thought leaders with the opportunity to ask their own what if questions. What if……

November 22, 2019

Listen to AiCure’s Laura Shafner WoW podcast from PharmaVoice

How many ways is AI is disrupting the industry pipeline? We invite you to listen to this episode of WoW…

November 19, 2019

6 AI Healthcare Solutions for Remote Patient Monitoring

6 AI Healthcare Solutions for Remote Patient Monitoring November 16, 2019 It’s no secret that big tech companies like…

Intellectual property - Over 100 patents filed

Treatment Observation

Advanced Interaction

AI Methodologies

Computational DX

Fraud Detection

Next-Gen Labeling

Analytics

Other